Calyx Announces Partnership With Ceretype Neuromedicine

Calyx has announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

The Ceretype platform utilizes fMRI and artificial intelligence to connect neural circuitry to patient behaviors and treatment outcomes, delivering the objective biologic endpoints for more precise measurement of treatment effects during central nervous system drug development.

Reference

Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development. (2023, April 4). Cision PR Newswire.